JournalArta
Monday, October 12, 2026 · JakartaS&P 7,811.54 ▲0.59%USD/IDR 17,879 ▲0.40%Subscribe
JournalArta
Global Edition
beyond headlines
Advertisement
Markets · Stocks

GSK Stock Analysis: Gains 0.84%, Testing Support Level

On October 9, 2026: price 1,750.00 GBp, trend downtrend, RSI 36.5, support 1,735.50, resistance 1,911.00. technical analysis of gsk stock.

By Elena Vance
October 12, 20264 min read
GSK Stock Analysis: Gains 0.84%, Testing Support Level
GSK Stock Analysis

Why GSK is in focus today

  • Trading near its 3-month low (1,735.50)
  • Downtrend extending (5-day change -1.66%)

Selected automatically from 16 LSE (UK) stocks by a technical-signal score with daily weighted randomisation — not a recommendation.

GSK traded at 1,750.00 GBp on the London Stock Exchange on 9 October, according to market data from the exchange via Yahoo Finance, after the shares edged up 0.84% on the day. The move came as the stock remained close to its three-month low of 1,735.50 GBp, with a 1.66% decline over five days keeping the broader short-term trend pointed down. That is a fragile rebound.

Trend & Price Action

The price remains below both its 20-day simple moving average (SMA), at 1,835.28 GBp, and its 50-day SMA, at 1,859.30 GBp. A simple moving average smooths recent prices to show the direction of a trend; trading beneath both suggests sellers still have the upper hand. The 20-day average is also falling, down 0.50% over five days. There has been no recent crossover between the averages to signal a change in trend. GSK is positioned just above the 20-day support level of 1,735.50 GBp, which is also its three-month low. The 20-day resistance is 1,911.00 GBp. With the share price near the bottom of that range, the immediate question is whether support holds—not whether the latest one-day gain marks a recovery. As shown in the price chart, the falling averages and proximity to the lower Bollinger band frame the move as a test of support within a downtrend. Bollinger bands map a price range around an average: the lower band is 1,727.01 GBp, while the middle band is 1,835.28 GBp. The price’s position at just 11% of the band’s range indicates it is near the lower boundary, but that alone does not confirm a reversal.
Price action chart of GSK
3-month price action chart of GSK: price, SMA20/50, Bollinger, support & resistance. Data: exchange via Yahoo Finance.

Oscillators & Momentum

Momentum measures do not yet confirm a turn. The MACD is negative at -30.505, below its -20.413 signal line, and its histogram is also negative at -10.092. In plain terms, recent downward momentum remains stronger than the signal used to identify a possible shift. The RSI is 36.5, a neutral reading, while the Stochastic is oversold at 8.0 for %K and 12.1 for %D. RSI gauges the speed of price moves; Stochastic compares a closing price with its recent range. An oversold reading can reflect sustained selling, not necessarily an imminent bounce. The contrast matters: Stochastic signals pressure has become stretched, but MACD has yet to show that pressure easing. As the momentum chart shows, the indicators are mixed rather than aligned behind a reversal: Stochastic is deeply oversold, while MACD remains negative.
Momentum chart of GSK
Momentum chart of GSK: RSI(14), MACD, Stochastic. Data: exchange via Yahoo Finance.

Volatility, Volume & Key Levels

The Bollinger band width is 11.8%, classified as normal, so the data do not point to an unusually tight squeeze or a sharp expansion in volatility. Average true range (ATR), a measure of typical price movement, is 41.66 GBp, or 2.4% of the share price—consistent with moderate volatility. Trading volume was 6,931,381 shares, around 1.0 times its 20-day average of 7,245,664. That is close to normal participation, not a conspicuous surge behind the daily rise. On-balance volume (OBV), which tracks buying and selling pressure through volume, is falling. Together, these readings offer little evidence that buyers have taken control. Support at 1,735.50 GBp is the immediate line to watch. A sustained break below it would put the shares beneath both the 20-day support and three-month low. If that floor holds, a rebound would still need to reclaim the 1,835.28 GBp 20-day average before the short-term trend looks less weak; 1,911.00 GBp remains the 20-day resistance.

Technical Verdict: HOLD (wait & see)

The indicators support a cautious, conditional reading rather than a clear directional signal. The price is below both moving averages and the 20-day average is falling. MACD remains negative, while OBV is declining. Against that, Stochastic is oversold and the price is near the lower Bollinger band—conditions that may leave room for a bounce but do not confirm one. The verdict is invalidated if the price falls below 1,735.50 GBp, the stated support and three-month low. - Ideal entry range: 1,735.50–1,835.28 GBp, bounded by support and the 20-day SMA. - Exit target: 1,911.00 GBp, the 20-day resistance. - Stop-loss protection: Below 1,727.01 GBp, the lower Bollinger band. For non-traders, HOLD means the chart has not yet shown whether support will hold or the downtrend will resume. Data table — GSK.L, market data via Yahoo Finance, 9 October 2026, 23:03 WIB | Measure | Reading | |---|---:| | Last price | 1,750.00 GBp | | Daily change | +0.84% | | Five-day change | -1.66% | | 20-day SMA / 50-day SMA | 1,835.28 / 1,859.30 GBp | | RSI / Stochastic %K and %D | 36.5 / 8.0 and 12.1 | | MACD / signal / histogram | -30.505 / -20.413 / -10.092 | | Support / resistance | 1,735.50 / 1,911.00 GBp | | Three-month high / low | 2,096.00 / 1,735.50 GBp |

Summary Data GSK

Last price1,750.00 GBp
Change 1 day / 5 days / 1 month0.84% / -1.66% / -1.16%
Trend / MA-crossdowntrend / none
SMA20 / SMA501,835.28 / 1,859.30
RSI (14) / Stochastic %K36.5 / 8.0
Bollinger %B / ATR11% / 41.66
Support / Resistance 20 days1,735.50 / 1,911.00
Data as of9 October 2026 23:03 WIB

Disclaimer: This technical analysis is generated automatically from exchange data (via Yahoo Finance) and indicators calculated by JournalArta, for information and education only. The verdict and the entry, target and stop-loss levels are not investment advice or a solicitation to buy or sell any security. Investment decisions and their risks rest solely with the reader.

Advertisement
Advertisement
Advertisement